Skip to main content
  • Login
  • Contact
  • Subscribe
  • Advertise With Us

Search form

Home

The Pilot News

Plymouth weather info

  • Home
    • Forms
  • News
    • Local News
    • The Leader of Starke County
    • Culver Citizen
    • Business News
  • Sports
  • Obituaries
  • Classifieds
    • Place an Ad
    • Classified Display Ads
  • Entertainment
    • Calendar
    • Best Of
    • Special Sections
    • Talking About...
    • Games
  • Photos
  • Videos
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Neurotrope Inc (NQ: NTRP)
5.645 USD  -0.185 (-3.17%)
Official Closing Price  /  Updated: 4:00 PM EDT, Aug 20, 2019  /  Add to My Watchlist      
View: Quote
Overview
Detailed Quote
Charting
Historical Prices
 News
All News
Press Releases
Related Stories
Blogs
 Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 109,400
Open 5.830
Bid (Size) 4.640 (1)
Ask (Size) 6.050 (5)
Prev. Close 5.830
Today's Range 5.500 - 5.959
52wk Range 3.330 - 9.500
Shares Outstanding 7,907,527
Dividend Yield N/A
Performance
YTD
+51.34%
+51.34%
1 Month
+2.82%
+2.82%
3 Month
-21.27%
-21.27%
6 Month
+30.67%
+30.67%
1 Year
-37.28%
-37.28%
Top News
More News
Neurotrope Announces Publication Highlighting the Potential of Bryostatin as a Unique Neurorestorative Therapy
August 13, 2019
-Analysis in Journal, Trends in Pharmacological Sciences, Outlines Bryostatin's Transformative Potential in Combating Alzheimer's Disease- Read More
from PR Newswire
Neurotrope Announces Corporate Update and Reports Second Quarter 2019 Financial Results
August 05, 2019
-- Concluded Data Collection in Confirmatory Phase 2 Study of Bryostatin-1 in Moderate to Severe Alzheimer's Disease; Top-line Data Expected During the Third Quarter of 2019 -- Read More
from PR Newswire
More News
Read More
Ellis Martin Report with Neurotrope's (NASDAQ:NTRP) Dr. Daniel Alkon: Reversing Alzheimer's Disease.
August 19, 2019
from ABN Newswire
Neurotrope Strategic Advisory Board Members Participating in Key Opinion Leader Call Sponsored by Oppenheimer's Biotechnology Team
July 17, 2019
from PR Newswire
Neurotrope Concludes Data Collection in Confirmatory Phase 2 Clinical Trial of Moderately Severe to Severe Alzheimer's Disease
July 15, 2019
from PR Newswire
Neurotrope to Present at the Alzheimer's Association International Conference; Neurotrope President and Chief Scientific Officer, Dr. Daniel L. Alkon, to Receive Cure Coin Award; Design of Confirmator
July 11, 2019
from PR Newswire
Neurotrope CEO to Present at the Maxim Group Key Opinion Leader Discussion on Alzheimer's Disease on June 26th, 2019
June 24, 2019
from PR Newswire
Neurotrope's President and Chief Scientific Officer to Present at the Alzheimer's Solutions Conference at The University of the Sciences in Philadelphia, PA on June 3rd, 2019
June 03, 2019
from PR Newswire
Neurotrope to Present at the LD Micro 9th Annual Invitational Conference on June 4, 2019
May 30, 2019
from PR Newswire
Neurotrope Announces Inducement Grant to Newly-Appointed Chief Operating Officer and General Counsel
April 19, 2019
from PR Newswire
New Research: Key Drivers of Growth for Seritage Growth Properties, TrovaGene, VistaGen Therapeutics, Tecogen, Neurotrope, and Stellar Biotechnologies — Factors of Influence, Major Initiatives and Sus
April 19, 2019
from GlobeNewswire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Copyright © 2019 The Pilot News | 214 N. Michigan | Plymouth, IN 46563 | (574) 936-3101 • 800-933-0356
All property rights for the entire contents of this publication shall be the property of The Pilot News.
No part hereof may be reproduced without prior written consent.
Privacy and Terms of Use


Site Design, Programming & Development by Surf New Media